Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Here's the next installment of the panel discussion on molecular markers from the webinar in Santa Monica with Drs. Charlie Rudin, Alice Shaw, David...
I'm happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on " Molecular Markers in Advanced...
This is the first of a series of podcasts from the two hour special webinar we did in partnership with the LUNGevity Foundation at the Santa Monica...
This is the third and final part of Dr. Weiss's presentation on "Highlights in Lung Cancer, 2011". After focusing on developments in relatively narrow...
Here is the second part of the presentation on "Lung Cancer Highlights, 2011" by Dr. Jared Weiss. This section of his talk focuses on the striking...
We couldn't do what we do without you, our volunteers! From helping at the ASCO booth, admin and transcription work, to spreading pamphlets and...
Who should be tested for ALK? How is ALK tested and how reliable are the results? In this video, the doctors discuss several issues surrounding the issue of testing for ALK, including what the medical guidelines suggest for testing lung cancer patients for genetic mutations.
Xalkori (crizotinib) was one of the fastest approved drugs in cancer treatment history because of its high efficacy levels in ALK positive lung cancer patients. In this video, the doctors discuss what took place as it raced to approval, as well as the limitations and side effects of the drug.
[powerpress]
The doctors discuss the history of ALK in lung cancer treatments and what the ALK rearrangement means for patients.
Here's the pdf for this presentation: Inherited T790M EGFR Mutation
Here is a brief and basic summary of the concept of why we're concerned not only about the cancer we can see but the potential cancer we can't.
One of the challenges of cancer care is that we guide our treatments by what clinical trial evidence tells us is best for particular patient populations. However, trials exclude patients who have significant medical issues other than cancer.
This week, the American Academy of Family Physicians (AAFP) elected to not follow the lead of the more influential US Preventive Services Task Force (USPSTF), which previously reviewed the information on chest CT screening for high risk patients and recommended it, and
Every few months I see a patient who reminds me of the fallability of mutation testing.
Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.
[powerpress]
For all too many people with lung cancer or caring for someone with it, the concept that lung cancer may not be threatening may seem sacrilegious. It is, after all, by far the leading cause of cancer deaths in the US in both men and women, far ahead of both breast cancer and prostate cancer in its fatality rate, though breast cancers and prostate cancers are more commonly diagnosed in women and men respectively.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.